Telix Pharmaceuticals is trading at $8.85, down 6.07% before the November 6, 2026 session amid a sharp technology-led market sell-off and broad risk aversion. - Healthcare was also lower in pre-market, though less sharply. - No clear company-specific negative catalyst emerged in the search. - Recent company news included joining a theranostics initiative; its November 4 Capital Markets Day discussed revenue guidance and the proposed ITM acquisition.